133 related articles for article (PubMed ID: 7931147)
1. Particle assembly and Vpr expression in human immunodeficiency virus type 1-infected cells demonstrated by immunoelectron microscopy.
Wang JJ; Lu Y; Ratner L
J Gen Virol; 1994 Oct; 75 ( Pt 10)():2607-14. PubMed ID: 7931147
[TBL] [Abstract][Full Text] [Related]
2. Effects of mutant Vpr/Vpx on HIV-2 assembly demonstrated by immunoelectron microscopy.
Wan JJ; Ratner L
Proc Natl Sci Counc Repub China B; 2001 Jan; 25(1):50-8. PubMed ID: 11254173
[TBL] [Abstract][Full Text] [Related]
3. Efficient HIV-1 replication can occur in the absence of the viral matrix protein.
Reil H; Bukovsky AA; Gelderblom HR; Göttlinger HG
EMBO J; 1998 May; 17(9):2699-708. PubMed ID: 9564051
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
5. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation.
Yao XJ; Subbramanian RA; Rougeau N; Boisvert F; Bergeron D; Cohen EA
J Virol; 1995 Nov; 69(11):7032-44. PubMed ID: 7474123
[TBL] [Abstract][Full Text] [Related]
6. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.
Connor RI; Chen BK; Choe S; Landau NR
Virology; 1995 Feb; 206(2):935-44. PubMed ID: 7531918
[TBL] [Abstract][Full Text] [Related]
7. Vpr-GFP virion particle identifies HIV-infected targets and preserves HIV-1Vpr function in macrophages and T-cells.
Muthumani K; Montaner LJ; Ayyavoo V; Weiner DB
DNA Cell Biol; 2000 Mar; 19(3):179-88. PubMed ID: 10749170
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus vpr gene encodes a virion-associated protein.
Yuan X; Matsuda Z; Matsuda M; Essex M; Lee TH
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1265-71. PubMed ID: 2150318
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.
Paxton W; Connor RI; Landau NR
J Virol; 1993 Dec; 67(12):7229-37. PubMed ID: 8230445
[TBL] [Abstract][Full Text] [Related]
10. Construction of human immunodeficiency virus 1/simian immunodeficiency virus strain mac chimeric viruses having vpr and/or nef of different parental origins and their in vitro and in vivo replication.
Kuwata T; Igarashi T; Ido E; Jin M; Mizuno A; Chen J; Hayami M
J Gen Virol; 1995 Sep; 76 ( Pt 9)():2181-91. PubMed ID: 7561755
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr.
Di Marzio P; Choe S; Ebright M; Knoblauch R; Landau NR
J Virol; 1995 Dec; 69(12):7909-16. PubMed ID: 7494303
[TBL] [Abstract][Full Text] [Related]
12. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
Wu X; Liu H; Xiao H; Kappes JC
Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
[TBL] [Abstract][Full Text] [Related]
13. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx.
Wu X; Liu H; Xiao H; Kim J; Seshaiah P; Natsoulis G; Boeke JD; Hahn BH; Kappes JC
J Virol; 1995 Jun; 69(6):3389-98. PubMed ID: 7745685
[TBL] [Abstract][Full Text] [Related]
14. Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.
Kobinger GP; Borsetti A; Nie Z; Mercier J; Daniel N; Göttlinger HG; Cohen A
J Virol; 1998 Jul; 72(7):5441-8. PubMed ID: 9620999
[TBL] [Abstract][Full Text] [Related]
15. Incorporation of Vpr into human immunodeficiency virus type 1: role of conserved regions within the P6 domain of Pr55gag.
Checroune F; Yao XJ; Göttlinger HG; Bergeron D; Cohen EA
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):1-7. PubMed ID: 7648278
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than gag and is phosphorylated in infected cells.
Müller B; Tessmer U; Schubert U; Kräusslich HG
J Virol; 2000 Oct; 74(20):9727-31. PubMed ID: 11000245
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion.
Cavrois M; Neidleman J; Yonemoto W; Fenard D; Greene WC
Virology; 2004 Oct; 328(1):36-44. PubMed ID: 15380356
[TBL] [Abstract][Full Text] [Related]
18. Antiviral effects of mifepristone on human immunodeficiency virus type-1 (HIV-1): targeting Vpr and its cellular partner, the glucocorticoid receptor (GR).
Schafer EA; Venkatachari NJ; Ayyavoo V
Antiviral Res; 2006 Dec; 72(3):224-32. PubMed ID: 16889838
[TBL] [Abstract][Full Text] [Related]
19. Virion-targeted viral inactivation: new therapy against viral infection.
Okui N; Kitamura Y; Kobayashi N; Sakuma R; Ishikawa T; Kitamura T
Mol Urol; 2001; 5(2):59-66. PubMed ID: 11690549
[TBL] [Abstract][Full Text] [Related]
20. Identification of residues in the N-terminal acidic domain of HIV-1 Vpr essential for virion incorporation.
Mahalingam S; Khan SA; Jabbar MA; Monken CE; Collman RG; Srinivasan A
Virology; 1995 Feb; 207(1):297-302. PubMed ID: 7871742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
